Takeda Adds Niaspan, Advicor To U.S. Product Line Via Deal With Kos
Executive Summary
Takeda is expanding its marketing presence in the U.S. via a deal with Kos to promote the cholesterol drugs Niaspan and Advicor
You may also be interested in...
Kos Will Re-Launch Teveten And Cardizem LA In June Following Biovail Deal
Kos will re-launch Biovail's three cardiovascular products in June following the addition of 150 Biovail reps to its sales team
Kos Will Re-Launch Teveten And Cardizem LA In June Following Biovail Deal
Kos will re-launch Biovail's three cardiovascular products in June following the addition of 150 Biovail reps to its sales team
Sales Force Bubble May Soon Burst; Slowing R&D Is Cause, Takeda Says
Industry has reached a peak in terms of sales force expansion after years of annual increases, Takeda VP-Sales Dean Hart said Nov. 19 at a conference sponsored by The Economist in Philadelphia